慢性乙型肝炎抗病毒治疗现状及展望

Antiviral therapy for chronic hepatitis B: current status and perspectives

慢性乙型肝炎是影响我国公共健康的重要问题之一。乙型肝炎抗病毒治疗的药物包括两大类:IFN以及核苷和核苷酸类药物。尽管现有药物已经可使大部分患者实现持续的HBV抑制,但仍有大部分患者无法实现免疫控制和功能性治愈。未来,随着新靶点药物研发的进展,相信人类在不久的将来,会像战胜HCV一样,战胜HBV。

Chronic hepatitis B is an important public health issue in China. The drugs used as the antiviral therapy for hepatitis B are mainly interferons and nucleos（ t） ide analogues. Although these drugs have realized persistent HBV inhibition in most patients,a large number of patients cannot achieve immune control and functional cure. It is believed that in the future,with the research and development of new target drugs,we will defeat HBV in the way we defeated HCV.